Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. - Wikidata - awgldk - TriplyDB

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

http://www.wikidata.org/entity/Q37116929

about

Systemic delivery of oncolytic viruses: hopes and hurdles Oncolytic viruses: finally delivering Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications Development of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based Constructs Circumventing antivector immunity: potential use of nonhuman adenoviral vectors Oncolytic adenovirus-mediated therapy for prostate cancer Traceless bioresponsive shielding of adenovirus hexon with HPMA copolymers maintains transduction capacity in vitro and in vivo A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route Polymeric Cups for Cavitation-mediated Delivery of Oncolytic Vaccinia Virus.The influence of blood on targeted microbubbles Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasound Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus The influence of innate and pre-existing immunity on adenovirus therapy CR1/2 is an important suppressor of Adenovirus-induced innate immune responses and is required for induction of neutralizing antibodies Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.Oncolytic adenovirus modified with somatostatin motifs for selective infection of neuroendocrine tumor cells.Biodistribution and retargeting of FX-binding ablated adenovirus serotype 5 vectors Presence of IgG anti-gp160/120 antibodies confers higher HIV capture capacity to erythrocytes from HIV-positive individuals.Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins Helper-dependent adenoviral vectors for liver-directed gene therapy.Rapamycin enhances adenovirus-mediated cancer imaging and therapy in pre-immunized murine hosts Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer.Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor X-dependent cell interaction in vitro and in vivo Incorporation of Peptides Targeting EGFR and FGFR1 into the Adenoviral Fiber Knob Domain and Their Evaluation as Targeted Cancer Therapies Alzheimer's Disease: APP, Gamma Secretase, APOE, CLU, CR1, PICALM, ABCA7, BIN1, CD2AP, CD33, EPHA1, and MS4A2, and Their Relationships with Herpes Simplex, C. Pneumoniae, Other Suspect Pathogens, and the Immune System Protection of adenovirus from neutralizing antibody by cationic PEG derivative ionically linked to adenovirus Amphiphilic core-shell nanoparticles containing dense polyethyleneimine shells for efficient delivery of microRNA to Kupffer cells.Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.Ad5:Ad48 hexon hypervariable region substitutions lead to toxicity and increased inflammatory responses following intravenous delivery Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques The relevance of coagulation factor X protection of adenoviruses in human sera.Adenovirus activates complement by distinctly different mechanisms in vitro and in vivo: indirect complement activation by virions in vivo.In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.Identification of coagulation factor (F)X binding sites on the adenovirus serotype 5 hexon: effect of mutagenesis on FX interactions and gene transfer.Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies.Strategies to overcome host immunity to adenovirus vectors in vaccine development.Helper-Dependent Adenoviral Vectors.

P2860

Q21284969-C01614B2-68EF-42F4-B524-C80EB3DA1FDA Q26772039-77B1D732-B869-4A6C-B138-F1A1729FE7D1 Q26776553-B599A1C8-4451-402F-A6E5-EF6CF2FB99C0 Q26782083-21AF0CFA-EB24-4B32-9DCA-96D2762C539B Q26995655-A68ADD89-3694-4170-B929-59F27DEE4500 Q27004796-6927A5BC-034A-45B1-B5E4-880E1B94D20A Q28539158-0A31F4D7-44CA-4764-9161-C57198B411A6 Q28817910-AA84696C-A788-4366-A2FB-CC3C4907125A Q30369123-3AF24AD5-C846-4556-B0B9-E7492EA1B416 Q30399305-B37C4940-F353-418C-8564-6B70DBDFCA3D Q30433651-2F469C82-6D07-4712-9679-17895165D71F Q30446996-CCD8F046-95CE-428A-8D2C-FB3381E04C84 Q33633287-2BD37012-6044-4977-B339-045E24619CB5 Q33655401-5E254D88-8BD6-4708-BB05-AE554DAFF3F8 Q33687979-AA4C945E-26B9-4754-80E3-7E219336C0B9 Q33690982-F7E32D0A-3C78-4777-8263-F4A5D700F23F Q33906116-7691E11A-ADBA-4E08-91C4-37A1B6A6077F Q34178183-D9A69856-B2C2-4C57-86EF-F5BF120A3A94 Q34282191-B36F18E7-4C3D-4BFD-803B-D39B60644582 Q34438445-E20B10BD-F546-4B8E-960E-2750C380B2D3 Q34765825-E501A400-7B3A-47C2-B586-C3141ED936E4 Q34982825-B614B164-7B9D-4507-9A98-F58DD6FC4DB1 Q34984515-861257C1-26E2-4182-B836-3EE1D3828896 Q35256725-559CBE11-3A0A-46A1-866D-8822EAEA73C1 Q35557004-F4B584C2-217B-4A0E-B04E-36ACB8BD5273 Q35641791-7976CDF6-57D8-4975-9894-F154899CA280 Q35664117-97719B22-9B9F-4983-A3E7-2EB79D75F0F2 Q35821087-D92C4E90-7F68-4820-987F-5BA5601DE0B9 Q36065583-290CDD16-8DDD-4B4F-B490-12A42174F123 Q36220624-26D3E570-C698-48CF-B0C4-BD64CCF27B3D Q36380295-6057CFCC-0711-4F1C-AC78-B1A3109D4D0B Q36445557-6AF093AF-D2F5-4BF5-8CA6-4091F336B722 Q36756690-DA6EF212-59CC-4AAC-B18B-D45A64DEF137 Q37085147-2D250714-E860-4779-813C-B8E67D9802B7 Q37191878-082CC3F1-581D-471E-B9B5-A1E4620BD3FC Q37232834-FCC4BF83-0114-48C0-9650-8A7D888B8CFF Q37291653-B4EA7229-DA85-4A57-B46E-CCF434CAF7FF Q37317439-1A258E35-6EFE-4805-B7FE-4E8D5F0A314F Q37503253-970FC567-72AC-4EA3-80EC-2658DBDB9644 Q37582126-48358780-406D-4D7B-A03C-BE053A8F7301

P2860

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.

http://www.wikidata.org/entity/Q37116929

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Human erythrocytes bind and in ...... tor and complement receptor 1.

@en

Human erythrocytes bind and in ...... tor and complement receptor 1.

@nl

type

label

Human erythrocytes bind and in ...... tor and complement receptor 1.

@en

Human erythrocytes bind and in ...... tor and complement receptor 1.

@nl

prefLabel

Human erythrocytes bind and in ...... tor and complement receptor 1.

@en

Human erythrocytes bind and in ...... tor and complement receptor 1.

@nl

P1433

Q37116929-935672C6-85B0-4746-8458-AAC694458138

P1476

Q37116929-89B99D2C-4C4A-4562-9A39-E6FC083A907E

P2093

Q37116929-125977A4-4702-41E4-A1CB-81FA08F8F9B3

Q37116929-58DE19DD-CDE2-4133-87D6-BEB0C5E66B98

Q37116929-6FA9C0EC-444A-417A-8E0C-5AC58EEE722A

Q37116929-70FB24FA-1D0B-44BA-A60D-3878E7B83C30

Q37116929-75B4C2C2-51DE-4A0E-9184-B046AB2E7893

Q37116929-7D70A9CB-5A59-43DD-9BBF-76FABE5325F1

Q37116929-A0490A1D-BBA0-4FAF-8CB4-528275BEB836

Q37116929-A193D392-3EA5-4E05-A115-9095D59EF9D2

Q37116929-B4E53BAF-0F3F-46F1-9DDA-4AB1980B8D2F

Q37116929-FA4BF70F-94B7-43FA-A0A8-E9A0C4545DF8

P2860

Q37116929-04801555-5262-4551-B189-ED3423A54ACF

Q37116929-095F58BF-01B9-40C1-9039-60492EB74BF0

Q37116929-097533C0-C870-4659-81E6-CDBD3FC11751

Q37116929-0A430742-60C3-4051-AA0D-6366FF289BCA

Q37116929-0BE87260-0D19-4783-A62D-CC26EC138FC8

Q37116929-1517B008-4EEB-4F92-BA7F-A86608701229

Q37116929-161210E2-CE36-42B6-9BDD-C9E8148CAE7C

Q37116929-1745403E-9E4E-4020-A11A-EBD528A68F2F

Q37116929-22106977-6CBF-41F6-8F5C-AC5368B3F1EE

Q37116929-2B15314F-4905-4E49-9AE8-06710F6289E7

P304

Q37116929-60FC2526-F830-4270-BB95-0FF89C7DB962

P31

Q37116929-AB612D69-7B84-4A09-BF52-59148BD5DC30

P356

Q37116929-00E60A05-9101-450F-87A8-4EB62CE4019D

P407

Q37116929-8126FACE-6760-4149-814C-0CC4AC38B20F

P433

Q37116929-04E526EF-480A-4767-9DC1-EE3927656553

P478

Q37116929-D96332AE-2819-4FFD-AC5A-701E206A09B1

P50

Q37116929-807F2534-791A-4D78-A692-F6D8B28A8789

Q37116929-81CA5806-AD35-4CD6-80D7-02AF1B91EFF4

Q37116929-DF241316-97CC-4E2C-BB6A-679CEA7669CF

P577

Q37116929-57849691-3513-47B8-A0CB-F51192B97454

P5875

Q37116929-7C33878F-AC2D-4221-8677-54A37AF0C741

P698

Q37116929-AB4B4BD5-4828-4A32-BD61-AA5DC51D91F2

P921

Q37116929-43EBD332-0258-4557-9FE2-A183F08ABCDF

P932

Q37116929-9DA1E657-5C43-4BF4-8856-A8D97DC5F29A

P356

BLOOD-2008-09-178459

P1433

P1476

Human erythrocytes bind and in ...... tor and complement receptor 1.

@en

P2093

Andreas F-P Sonnen

http://www.w3.org/2001/XMLSchema#string

Anna M Cerny

http://www.w3.org/2001/XMLSchema#string

Karel Ulbrich

http://www.w3.org/2001/XMLSchema#string

Kerry D Fisher

http://www.w3.org/2001/XMLSchema#string

Leonard W Seymour

http://www.w3.org/2001/XMLSchema#string

Nicola K Green

http://www.w3.org/2001/XMLSchema#string

Robert C Carlisle

http://www.w3.org/2001/XMLSchema#string

Robert J C Gilbert

http://www.w3.org/2001/XMLSchema#string

Robert W Finberg

http://www.w3.org/2001/XMLSchema#string

Ying Di

http://www.w3.org/2001/XMLSchema#string

P2860

The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction

The coxsackievirus and adenovirus receptor interacts with the multi-PDZ domain protein-1 (MUPP-1) within the tight junction

HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses

Structure and biology of complement protein C3, a connecting link between innate and acquired immunity

Effect of gene therapy on visual function in Leber's congenital amaurosis

Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5

The coxsackievirus-adenovirus receptor protein as a cell adhesion molecule in the developing mouse brain

Primate erythrocyte-immune complex-clearing mechanism.

Adenovirus-induced thrombocytopenia: the role of von Willebrand factor and P-selectin in mediating accelerated platelet clearance.

The first step of adenovirus type 2 disassembly occurs at the cell surface, independently of endocytosis and escape to the cytosol.

P304

1909-1918

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-09-178459

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23766325

http://www.w3.org/2001/XMLSchema#string

P698

19131551

http://www.w3.org/2001/XMLSchema#string

P921

P932

2651010

http://www.w3.org/2001/XMLSchema#string